Varinder Jeet
Positions
- Postdoctoral Research Fellow, APCRC-Q
- Member, IHBI, QUT
Related websites and profiles
Qualifications
- PhD, Medicine, University of New South Wales, Australia, 2009
- MSc, Biotechnology, Punjabi University, India, 2003
- BSc, Punjab University, India, 2001
Biography
Dr Varinder Jeet completed his PhD studies from the University of New South Wales, Sydney in 2009. He received a Masters degree in Biotechnology from Punjabi University, India. He started his PhD in 2005 after receiving the Sydney Foundation of Medical Research Postgraduate Scholarship. During his PhD, he investigated various aspects of prostate cancer (PC) including development of a suitable model for prostate cancer progression, study of mechanisms underlying advanced PC and targeted gene therapy mediated approaches to curb the growth and proliferation of PC cells.
Soon after completing his PhD, he moved to Brisbane to work on the dendritic cell based cancer immunotherapy at the Mater Hospital, Brisbane. His current project at APCRC - Q involves the identification and targeting of various molecular markers that underlie the progression of prostate cancer towards androgen independence.
Research interests
identification of the molecular changes, progression of prostate cancer, androgen independence, high-throughput bioprofiling, screening, validation, and functional evaluation of targets
Top publications
- Jeet V, Tevz G, Lehman M, Hollier B, Nelson C. Elevated YKL40 is associated with advanced prostate cancer (PCa) and positively regulates invasion and migration of PCa cells. Endocr Relat Cancer. Oct 2014; 21(5): 723–737 doi: 10.1530/ERC-14-0267. Epub 2014 Jun 30.
- Jeet V, Russell PJ, Verma ND, Khatri A. Targeting aurora kinases: a novel approach to curb the growth & chemoresistance of androgen refractory prostate cancer.
Current Cancer Drug Targets (2012 Feb), Bentham Science, ISSN: 1568-0096 (Print) 1873-5576 (Online) pp.144-63 doi: 10.2174/156800912799095180 - Jongbloed SL, Kassianos AJ, McDonald KJ, Clark GJ, Ju X, Angel CE, Chen CJ, Dunbar PR, Wadley RB, Jeet V, Vulink AJ, Hart DN, Radford KJ. Human CD141+ (BDCA-3)+ dendritic cells (DCs) represent a unique myeloid DC subset that cross-presents necrotic cell antigens. J Exp Med. 2010 Jun 7;207(6):1247-60. doi: 10.1084/jem.20092140. Epub 2010 May 17.
- Jeet V, Russell PJ, Khatri A. Modeling prostate cancer: a perspective on transgenic mouse models. Cancer Metastasis Rev. 2010 Mar;29(1):123-42. doi: 10.1007/s10555-010-9212-9.
- Jeet V, Ow K, Doherty E, Curley B, Russell PJ, Khatri A. Broadening of transgenic adenocarcinoma of the mouse prostate (TRAMP) model to represent late stage androgen depletion independent cancer. Prostate. 2008 Apr 1;68(5):548-62. doi: 10.1002/pros.20714.
